Clinical Scorecard: Integrative Clinical, Structural, and Cellular Analyses Differentiate Pathogenic from Benign Variants of TRPV4
At a Glance
Category
Detail
Condition
TRPV4 channelopathies including inherited neuromuscular diseases, skeletal dysplasias, and arthropathy
Key Mechanisms
Gain-of-function mutations in TRPV4 causing increased ion channel activity and cytotoxicity via altered calcium signaling and protein interactions
Target Population
Patients with TRPV4 variants presenting with neuromuscular symptoms, skeletal abnormalities, or arthropathy
Care Setting
Specialized neurology and genetic clinics with access to molecular diagnostics and functional assays
Key Highlights
Pathogenic TRPV4 mutations cause gain of ion channel function leading to increased intracellular calcium and toxicity.
Neuropathy-causing mutations cluster in the ankyrin repeat domain affecting RhoA interaction and cytoskeletal regulation.
TRPV4 antagonists rescue cellular toxicity in models, supporting potential therapeutic use in patients.
Guideline-Based Recommendations
Diagnosis
Use targeted or whole exome/genome sequencing to identify TRPV4 variants.
Combine clinical phenotyping with functional assays (ion channel activity, cytotoxicity, protein interactions) to assess pathogenicity.
Consider domain-specific mutation location (ankyrin repeat domain vs transmembrane domain) to differentiate pathogenic from benign variants.
Management
Consider TRPV4 antagonists as potential therapeutic agents based on preclinical rescue of toxicity.
Monitor for neuromuscular symptoms including vocal cord weakness, motor-predominant disease, and skeletal abnormalities.
Tailor management to phenotype severity and organ system involvement.
Monitoring & Follow-up
Regular clinical assessment of motor and sensory function, vocal cord and respiratory status.
Imaging and functional studies for skeletal dysplasia manifestations.
Genetic counseling and family screening for variant segregation and phenotype correlation.
Risks
Gain-of-function TRPV4 mutations can cause early-onset congenital disease with progressive neuromuscular impairment.
Late-onset sensory-predominant disease is more likely with benign or non-gain-of-function variants.
Potential toxicity from increased intracellular calcium and disrupted protein interactions.
Patient & Prescribing Data
Patients harboring TRPV4 gain-of-function mutations with neuromuscular or skeletal manifestations
Small molecule TRPV4 antagonists have demonstrated rescue of cellular toxicity in vitro and animal models, indicating promise for clinical trials and targeted therapy.
Clinical Best Practices
Integrate clinical, structural, and cellular data to classify TRPV4 variants for pathogenicity.
Focus on mutation location within TRPV4 domains to predict functional impact and clinical phenotype.
Employ multidisciplinary care including neurology, genetics, and orthopedics for comprehensive management.
Use functional assays to guide patient selection for emerging TRPV4-targeted therapies.
by Sarah H Berth, Linh Vo, Do Hoon Kwon, Tiffany Grider, Yasmine S Damayanti, Gage Kosmanopoulos, Andrew Fox, Alexander R Lau, Patrice Carr, Jack K Donohue, Maya Hoke, Simone Thomas, Chafic Karam, Alex J Fay, Ethan Meltzer, Thomas O Crawford, Rachelle Gaudet, Michael E Shy, Ute A Hellmich, Seok-Yong Lee, Charlotte J Sumner, Brett A McCray
From unexpected workplace parallels to kitchen-counter experiments and a few clinical twists, this set of stories covered more ground than your average shift.
